Company Snapshot: Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.
- Oct 9 2019 Genprex to Present at the MicroCap Rodeo Investor Conference
- Oct 7 2019 Genprex’s Pioneering Use of Non-Viral Delivery for Gene Therapy is Gaining Industry Support
- Sep 18 2019 Genprex to Present Via Webcast at the Singular Research Midwestern Values Conference on September 19, 2019
- Sep 11 2019 Independent Researchers Find Genprex’s TUSC2 Prevents Tumor Growth in Triple-Negative Breast Cancer